0001144204-17-062235.txt : 20171204 0001144204-17-062235.hdr.sgml : 20171204 20171204170206 ACCESSION NUMBER: 0001144204-17-062235 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20171204 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20171204 DATE AS OF CHANGE: 20171204 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENCISION INC CENTRAL INDEX KEY: 0000930775 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 841162056 STATE OF INCORPORATION: CO FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11789 FILM NUMBER: 171237733 BUSINESS ADDRESS: STREET 1: 6797 WINCHESTER CIRCLE CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 3034442600 MAIL ADDRESS: STREET 1: 6797 WINCHESTER CIRCLE CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: ELECTROSCOPE INC DATE OF NAME CHANGE: 19960502 8-K 1 tv480782_8k.htm FORM 8-K

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported) December 4, 2017

 

 

 ENCISION, INC.

(Exact name of registrant as specified in its charter)

 

Colorado 0-28604 84-1162056
(State or other jurisdiction
of incorporation)		 (Commission
File Number)		 (I.R.S. Employer
Identification No.)

 

6797 Winchester Circle, Boulder, Colorado 80301
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code (303) 444-2600

  

  

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 9.01Financial Statements and Exhibits.

 

(d)Exhibits.

  

99.1Press Release issued by ENCISION, INC., December 4, 2017

 

 

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  ENCISION, INC.
  (Registrant)
   
Date  December 4, 2017  
   
  /s/ Mala M Ray
  Mala M Ray
  Controller
  Principal Accounting Officer

 

 

 

 EX-99.1 2 tv480782_ex99-1.htm EXHIBIT 99.1

Encision Announces Death of VP-Product Development Officer Michael Biggs

BOULDER, Colo., Dec. 4, 2017 /PRNewswire/ -- Encision Inc. (OTC:ECIA) announced today that Michael Biggs, 48, its VP of Product Development died from injuries incurred from a bicycle accident.

Mr. Biggs was employed with Encision for five years and was promoted to the VP position in 2014. He held a B.S. degree from the University of California and an M.B.A. degree from the University of Colorado, and was a named inventor on over two dozen U.S. patents in the medical device field. To maintain continuity in the oversight of the VP-Product Development's functions, Dave Newton, our VP-Technology, will oversee the activities of product development.

"Our hearts are heavy with the loss of Mike Biggs," said Greg Trudel, President and CEO of Encision. "He was a brilliant colleague and a key contributor to our leadership team. Mike's passions and insights on medical devices helped Encision to deliver a cutting edge portfolio of products and his vision and contributions will enable Encision to continue to drive new levels of patient safety in laparoscopy. Our thoughts and prayers are with Mike's wife, children and family."

Encision Inc. designs and markets a portfolio of high performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit www.encision.com.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2017 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT: Mala Ray, Encision Inc., 303-444-2600, mray@encision.com